AbbVie

Claire Leurent pairs drug-development experience at Pfizer and Wyeth with cross-institutional venture investing at Samsung, J&J and the NIH, and—while teaching strategy at Northeastern—creates custom deal structures across stages.

Margarita Chavez serves as a board member at Aligos Therapeutics and works as a venture investor and advisor in the life sciences sector. Her board experience includes roles as chair and committee member across business development, finance, audit, and research and development functions. She has involvement in early-stage investment and mergers and acquisitions within the biotech industry.

Christina Vorvis is a Massachusetts‑based corporate VC who invests across oncology, immunology, neuroscience, eye care and aesthetics and pairs a PhD in cancer biology with startup and investment‑banking experience.

Donmienne Leung leads a dedicated European venture mandate and, after 20+ years as a drug hunter and PhD medicinal chemist with active publications, provides hands-on scientific guidance to biotech boards.

Doug Faunce, PhD immunologist and Head of Search & Evaluation for Eye Care, brings deep retina, glaucoma, front‑of‑eye expertise and focuses on external innovation and creative partnering from Irvine.

Joachim Vogt, based in Rhine‑Neckar, scouts European therapeutic and tech deals, acts as a front‑door partner at events, and pairs over a decade of business development with hands‑on scientific expertise.

Shawna Frazier, a San Francisco–based Director and West Coast lead focused on early-stage biotech, combines a Ph.D. scientific background and startup founder experience bridging big‑pharma strategy with Bay Area startups.

Christian Schubert is a hybrid operator-investor who shapes corporate venture strategy across US, Europe and Asia‑Pacific, pairing genetics, neurobiology and biochemistry training with large‑pharma experience and active biotech board involvement.